Equities analysts predict that Natus Medical Incorporated (NASDAQ:BABY) will report $121.74 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Natus Medical’s earnings, with estimates ranging from $121.18 million to $122.30 million. Natus Medical reported sales of $90.91 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.9%. The company is expected to issue its next earnings report on Wednesday, October 18th.

According to Zacks, analysts expect that Natus Medical will report full-year sales of $121.74 million for the current year, with estimates ranging from $505.01 million to $505.50 million. For the next financial year, analysts forecast that the company will report sales of $509.57 million per share, with estimates ranging from $506.56 million to $512.06 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Natus Medical.

Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The business had revenue of $122.20 million for the quarter, compared to analyst estimates of $121.99 million. During the same quarter in the prior year, the firm earned $0.39 EPS. The firm’s quarterly revenue was up 27.3% compared to the same quarter last year.

A number of research analysts recently commented on BABY shares. Benchmark Co. reaffirmed a “buy” rating and issued a $48.00 price target (down previously from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. TheStreet cut Natus Medical from a “b” rating to a “c+” rating in a research report on Thursday, April 27th. BidaskClub upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $45.00.

In other news, insider James B. Hawkins purchased 6,000 shares of Natus Medical stock in a transaction dated Wednesday, May 31st. The shares were bought at an average cost of $33.81 per share, for a total transaction of $202,860.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James B. Hawkins purchased 4,000 shares of Natus Medical stock in a transaction dated Thursday, June 15th. The shares were purchased at an average price of $33.98 per share, for a total transaction of $135,920.00. Following the completion of the acquisition, the insider now owns 578,023 shares of the company’s stock, valued at approximately $19,641,221.54. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in Natus Medical by 0.6% in the second quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock worth $154,779,000 after buying an additional 25,340 shares in the last quarter. Vanguard Group Inc. raised its position in Natus Medical by 2.9% in the second quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock worth $87,340,000 after buying an additional 66,676 shares in the last quarter. Columbia Wanger Asset Management LLC raised its position in Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares in the last quarter. Wellington Management Group LLP raised its position in Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Natus Medical by 10.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after buying an additional 151,372 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Natus Medical Incorporated (BABY) Expected to Announce Quarterly Sales of $121.74 Million” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/natus-medical-incorporated-baby-expected-to-announce-quarterly-sales-of-121-74-million/1478026.html.

Shares of Natus Medical (BABY) opened at 33.55 on Friday. Natus Medical has a 12-month low of $32.83 and a 12-month high of $44.39. The stock has a 50 day moving average of $36.43 and a 200 day moving average of $36.70. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 58.15 and a beta of 0.93.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.